已收盤 02-01 16:00:00 美东时间
0.000
0.00%
WINREVAIR significantly reduced the risk of clinical worsening events in recently diagnosed PAH patients over 70% of whom were on double background therapyHYPERION, third Phase 3 study to demonstrate significant efficacy
2025-06-23 18:48
Jan 28 (Reuters) - Platform Specialty Products Corp : * ORATION AN...
2019-01-28 20:23
Nov 1 (Reuters) - Platform Specialty Products Corp : * ANNOUNCES T...
2018-11-01 19:05